

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings of claims in the application:

LISTING OF CLAIMS:

Claims 1-22 (cancelled)

23. (new) A method for the enhancement of cognitive function and mental fatigue, comprising: administering to a subject in need thereof *Ginkgo* complexed with a phospholipid containing 10 to 50% of phosphatidylserine.

24. (new) The method according to claim 23 wherein the phospholipid contains from 20 to 40% of phosphatidylserine.

25. (new) The method according to claim 23 wherein the phospholipid contains 20% of phosphatidylserine.

26. (new) The method according to claim 23, wherein the *Ginkgo* is derived from the plant *Ginkgo biloba*, extracts thereof and/or one or more principal active substances thereof.

27. (new) The method according to claim 26, wherein one of the principal active substances is bilobalide.


28. (new) The method according to claim 26, characterized in that the *Ginkgo* extract is used containing at least about 20% *Ginkgo* flavone glycosides and about 2 to about 10% terpene lactones.

29. (new) The method according to claim 23, wherein the ratio between *Ginkgo* and the phosphatidylserine used to prepare the complex is about 1:1.

30. (new) The method according to claim 23, wherein the medicament or dietary supplement is administered in the form of tablets, granules, powders, capsules, syrups, solutions, suspensions, dragees, gels, injections or drops.

31. (new) The method according to claim 23, wherein the medicament or dietary supplement is formulated for oral administration.
32. (new) The method according to claim 23, wherein the *Ginkgo* phosphatidylserine complex contained in the medicament or dietary supplement is to be administered in an amount of about 20 to about 240 mg per day, particularly about 60 to about 120 mg per day.
33. (new) The method according to claim 23, wherein the medicament or dietary supplement additionally contains a pharmaceutically acceptable amount of at least one additive selected from the group comprising minerals, vitamins, sweeteners, flavors, pharmaceutically acceptable carriers, auxiliary and binder agents, excipients and mixtures thereof.
34. (new) The method according to claim 33, wherein the additive is selected from vitamins, minerals and mixtures thereof, particularly selected from calcium, fluorine, phosphorus, copper, potassium, manganese, magnesium selenium, zinc and iron, Vitamin A, Vitamins B1, B2 and B12, Vitamin C, Vitamin D2, nicotinamide, calcium pantotenate, rutoside and Vitamin E.
35. (new) A method for the enhancement of cognitive function and mental fatigue by improving the speed of memory and memory quality, by counteracting cognitive fatigue in normal, healthy persons or by preventing deterioration of the speed of memory in people with decreased cognitive functions, comprising administering to a subject in need thereof an effective amount of a *Ginkgo* complexed with phosphatidylserine.
36. (new) A method for the treatment and prevention of a disease related with the reduction of cognitive function and mental fatigue, comprising administering to a subject in need thereof an effective amount of a *Ginkgo* complexed with phosphatidylserine.
37. (new) The method according to claim 36 wherein the disease is Dementia.
38. (new) The method according to claim 37 wherein the disease is Alzheimer's Disease.

39. (new) The method according to claim 36 wherein the medicament or dietary supplement additionally contains a pharmaceutically acceptable amount of at least one additive selected from the group comprising vitamins, minerals, sweeteners, flavors, pharmaceutically acceptable carriers, auxiliary and binder agents, excipients and mixtures thereof.
40. (new) The method according to claim 36 in combination with a pharmaceutical compound used for the treatment and prevention of the disease to be treated related with the reduction of cognitive function and mental fatigue.
41. (new) The method according to claim 40, wherein the pharmaceutical compound is an acetylcholinesterase inhibitor.
42. (new) The method according to claim 40, wherein the additionally active compound is complexed grape seed extract.
43. (new) A pharmaceutical or dietary composition comprising *Ginkgo* complex and at least one vitamin and a pharmaceutically or dietarily acceptable carrier.
44. (new) A complex of an extract of *Ginkgo* with a phosphatidylserine of formula



wherein

R and R¹ each independently represent an acyl moiety selected from the fatty acids consisting of palmitic acid, oleic acid, linoleic acid, stearic acid.

45. (new) A complex according to claim 44, which comprises from 15 to 25% of saturated fatty acids, from 5 to 15% of mono-unsaturated fatty acids and from 60 to 80% of polyunsaturated fatty acids, based on the total acids.